Invention Grant
- Patent Title: Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
-
Application No.: US14909820Application Date: 2014-08-06
-
Publication No.: US10344092B2Publication Date: 2019-07-09
- Inventor: Leslie S. Johnson , Ling Huang , Kalpana Shah , Ezio Bonvini , Paul A. Moore , Wei Chen
- Applicant: MacroGenics, Inc.
- Applicant Address: US MD Rockville
- Assignee: MacroGenics, Inc.
- Current Assignee: MacroGenics, Inc.
- Current Assignee Address: US MD Rockville
- Agency: AuerbachSchrot LLC
- Agent William C. Schrot; Jeffrey I. Auerbach
- International Application: PCT/US2014/049848 WO 20140806
- International Announcement: WO2015/021089 WO 20150212
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C12P21/08 ; A61K39/395 ; A61K39/40 ; C07K16/28 ; C07K16/46 ; A61K39/00
Abstract:
The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.
Public/Granted literature
- US20160194396A1 Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof Public/Granted day:2016-07-07
Information query
